NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
NEWS Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer ByOncoscience 28. May 202217. July 2025
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
NEWS Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba ByOncoscience 7. April 201617. July 2025
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 200717. July 2025
NEWS Oncoscience AG and GenIlac agree on cooperation terms in Turkey ByOncoscience 7. July 201017. July 2025
NEWS Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine ByOncoscience 13. October 200717. July 2025
